Blonder Tongue Reports Fourth Quarter and Year End 2020 Results
Blonder Tongue Laboratories reported a 14.2% decline in net sales for Q4 2020, totaling $4.3 million, with a net loss of $2.4 million or $(0.23) per share. For the full year, sales fell 17.5% to $16.4 million, with a net loss of $(7.5 million) or $(0.76) per share. The company implemented significant operational restructuring, reducing costs by $940,000 in 2020. Key developments include over 15 new product introductions and a 35% increase in sales efforts towards telecom relationships. Despite challenges, the company aims for growth in 2021.
- Cost reductions of approximately $940,000 in 2020 compared to 2019.
- Introduced over 15 new products enhancing the product portfolio.
- Increased telecom sales relationships by over 35% year-over-year.
- Net sales decreased by $718,000 (14.2%) in Q4 2020 versus Q4 2019.
- Net loss of $(7.5 million) for FY 2020 compared to $(742,000) for FY 2019.
- Reliant on PPP loan forgiveness to ensure liquidity.
OLD BRIDGE, NJ / ACCESSWIRE / March 12, 2021 / Blonder Tongue Laboratories, Inc. (NYSE American:BDR) announced its sales and results for the fourth quarter and year ended December 31, 2020.
Commenting on the year end and fourth quarter results, Chief Executive Officer Ted Grauch noted, "Faced with a very difficult pandemic affected marketplace in 2020, the Company focused the year on completing a number of major organizational changes, R&D and intellectual property (IP) investments, product development, and inventory reduction programs. The acceleration of our operational restructuring in 2020 was completed along with streamlining both our manufacturing and engineering processes. The net result has been a lowering of the Company's operating costs by approximately
Blonder Tongue Laboratories, Inc. net sales decreased
The decrease in sales is primarily attributed to a decrease in sales of DOCSIS data products, digital video headend products, HFC distribution products and NXG IP video signal processing products offset by an increase in sales of transcoder products. Sales of DOCSIS data products were
For the year ended December 31, 2020, net sales decreased
The decrease is primarily attributable to a decrease in sales of digital video headend products, DOCSIS data products, contract manufacturing products, HFC distribution products and analog video headend products offset, in part, by an increase in sales of transcoder products. Sales of digital video headend products were
The Company's primary sources of liquidity have been its existing cash balances, cash generated from operations, amounts available under the MidCap Business Credit LLC revolving credit facility (the "MidCap Facility"), the proceeds received from a PPP loan, amounts available under the subordinated loan facility and cash generated from the private placement of common stock. The Company has completed all available draws under the current terms of the subordinated loan facility. During 2020, the Company received approximately
The Company plans to file its Annual Report as soon as is practicable but not later than March 31, 2021. In the Annual Report, the Company expects that the report of its independent registered public accounting firm will include an "Explanatory Paragraph-Going Concern." Although the Company has actively taken steps to address operating expenses and liquidity, there can be no assurance that those actions and others the Company intends to take in the future will be sufficient to address the concerns relating to the "Explanatory Paragraph-Going Concern."
Further commenting on the year end and fourth quarter results, Chief Executive Officer Ted Grauch noted,
"Despite the operating losses the Company incurred in 2020 due to the effects of the pandemic on our market demand and resulting sales, we believe the significant organizational changes and reductions in our monthly operating expenses in 2020, as well as our product line expansion and growing customer engagements will put the Company in a position for long term sustainable growth as we see a market recovery happen. We believe that a major indicator of this fundamental change in the Company's structure and strength was our reduction in cash used in operating activities of
Conference Call Reminder
Details of the live teleconference:
Date: Friday, March 12, 2021
Time: 11:00 a.m. Eastern Time (10:00 a.m. CT, 8:00 a.m. PT)
Investor Dial-in (US & Canada Toll-Free): 888-506-0062
Entry Code: 762058
The audio replay will be available under Investor Related Information on the Blonder Tongue Investor Relations webpage.
About Blonder Tongue
Blonder Tongue Laboratories, Inc. is the oldest designer and manufacturer of telecommunications and cable television video transmission technology in the USA. The majority of our products continue to be designed and built in our state-of-the-art New Jersey facility, which has been the Company's home for more than 50 years. Blonder Tongue Labs offers U.S.-based engineering and manufacturing excellence with an industry reputation for delivering ultra-high reliability products. As a leader in cable television system design, the Company provides service operators and systems integrators with comprehensive solutions for the management and distribution of digital video, IPTV and high-speed data services, as well as RF broadband distribution over fiber, IP, and Coax networks for homes and businesses. Additional information on the Company and its products can be found at www.blondertongue.com
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The information set forth above includes "forward-looking" statements and accordingly, the cautionary statements contained in Blonder Tongue's Annual Report and Form 10-K for the year ended December 31, 2019 (See Item 1: Business, Item 1A: Risk Factors, Item 3: Legal Proceedings and Item 7: Management's Discussion and Analysis of Financial Condition and Results of Operations), and other filings with the Securities and Exchange Commission are incorporated herein by reference. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance or achievements that Blonder Tongue anticipates or expects may or will occur in the future should be considered "forward-looking" statements, including statements that use the words "believe", "expect", "anticipate", "project", "target", "intend", "plan", "seek", "estimate", "endeavor", "should", "could", "may" and similar expressions. In addition, any statements that refer to projections for our future financial performance, our anticipated growth trends in our business and other characterizations of future events or circumstances are forward-looking statements, including statements regarding our ability to continue as a going concern, our ability to maintain the listing of our shares on the NYSE American and the status of our efforts to obtain forgiveness of our PPP loan and eligibility for such forgiveness. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. Blonder Tongue undertakes no obligation to publicly revise or update these forward-looking statements to reflect events or circumstances that arise after the date hereof. Blonder Tongue's actual results may differ from the anticipated results or other expectations expressed in Blonder Tongue's "forward-looking" statements.
Contacts
Eric Skolnik
Chief Financial Officer
eskolnik@blondertongue.com
(732) 679-4000
Ted Grauch
Chief Executive Officer
tgrauch@blondertongue.com
(732) 679-4000
Blonder Tongue Laboratories, Inc.
Condensed Consolidated Summary of Operating Results
(unaudited, in thousands, except per share data)
Three months ended | Twelve months ended | |||||||||||||||
December 31, | December 31, | |||||||||||||||
2020 | 2019 | 2020 | 2019 | |||||||||||||
Net sales | $ | 4,327 | $ | 5,045 | $ | 16,379 | $ | 19,842 | ||||||||
Gross profit (loss) | 495 | (1,196 | ) | 3,018 | 3,431 | |||||||||||
Loss from operations | (2,305 | ) | (3,746 | ) | (7,114 | ) | (466 | ) | ||||||||
Net loss | $ | (2,413 | ) | $ | (3,842 | ) | $ | (7,474 | ) | $ | (742 | ) | ||||
Basic and diluted net loss per share | $ | (0.23 | ) | $ | (0.40 | ) | $ | (0.76 | ) | $ | (0.08 | ) | ||||
Basic and diluted weighted average shares outstanding | 10,286 | 9,662 | 9,898 | 9,603 | ||||||||||||
Blonder Tongue Laboratories, Inc
Condensed Consolidated Summary Balance Sheets
(in thousands)
(unaudited) | ||||||||
December 31, 2020 | December 31, 2019 | |||||||
Current assets | $ | 6,104 | $ | 12,174 | ||||
Property, plant and equipment, net | 429 | 392 | ||||||
Total assets | 11,130 | 18,347 | ||||||
Current liabilities | 5,534 | 8,369 | ||||||
Long-term liabilities | 4,359 | 2,615 | ||||||
Stockholders' equity | 1,237 | 7,363 | ||||||
Total liabilities and stockholders' equity | $ | 11,130 | $ | 18,347 |
SOURCE: Blonder Tongue Laboratories, Inc.
View source version on accesswire.com:
https://www.accesswire.com/635122/Blonder-Tongue-Reports-Fourth-Quarter-and-Year-End-2020-Results
FAQ
What were Blonder Tongue Laboratories' sales figures for Q4 2020?
How much did Blonder Tongue's net loss increase in 2020?
What operational changes did Blonder Tongue implement in 2020?
What is the impact of the PPP loan on Blonder Tongue's financials?